TamaBio Co., Ltd. has completed a third-party allocation of new shares (Round B) with funding from a Leading International Investor who invests in Cutting-Edge Technologies. TamaBio’s planned development products will significantly advance existing treatment technologies by applying discoveries made in clinical cases and experiments. With this capital increase, we aim to further accelerate development and quickly realize optimal solutions for patients. In addition, we will continue to work to strengthen our supply capacity and quality control and systems for products that have already begun clinical use.
For further details, please contact:
TamaBio Company Limited
Head Office : 402 Gran Creste 2-2-18 Sakai Musashino-shi Tokyo 180-0022 Japan
Medical device manufacturing / Class 1 manufacturing and sales Development
Manufacturing, and sales of Class IV highly controlled medical devices
Development, manufacturing, and sales of regenerative medical devices and other synthetic artificial biomembranes
Managing Director / CEO : Tetsuya Nagao